Sverige - svenska - Läkemedelsverket (Medical Products Agency)

newbury pharmaceuticals ab - teriflunomid - filmdragerad tablett - 14 mg - laktosmonohydrat hjälpämne; teriflunomid 14 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - bröst-neoplasmer - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Europeiska unionen - svenska - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multipel skleros - selektiva immunsuppressiva medel - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Europeiska unionen - svenska - EMA (European Medicines Agency)

ipsen pharma - cabozantinib - sköldkörtelnoplasmer - antineoplastiska medel - behandling av vuxna patienter med progressivt, oåterkalleligt lokalt avancerat eller metastatisk medulärt sköldkörtelkarcinom.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (som fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiska medel - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycytemi vera (pv)jakavi är indicerat för behandling av vuxna patienter med polycytemi vera som är resistenta eller intoleranta av hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - multipel skleros, skovvis förlöpande - immunsuppressiva, selektiva immunsuppressiva - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Europeiska unionen - svenska - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastiska medel - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Europeiska unionen - svenska - EMA (European Medicines Agency)

teva b.v. - fentanyl - pain; cancer - smärtstillande medel - effentora är indicerat för behandling av genombrottssmärta (btp) hos vuxna cancerpatienter som redan tar opioider som underhållsbehandling för långvarig cancersmärta. btp är en övergående försämring av smärta som uppträder mot en bakgrund av i övrigt kontrolleras ihållande smärta. patienter som får underhåll opioid terapi är de som tar minst 60 mg oralt morfin dagligen, minst 25 mikrogram av transdermalt fentanyl per timme, minst 30 mg oxikodon dagligen, minst 8 mg oralt hydromorphone dagligen eller en equianalgesic dos av en annan opioid för en vecka eller längre.

Europeiska unionen - svenska - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetinhydroklorid - urininkontinens, stress - psychoanaleptics, - yentreve är indicerat för kvinnor för behandling av måttlig till svår stressininkontinens (sui).

Europeiska unionen - svenska - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multipel skleros, skovvis förlöpande - immunsuppressiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).